NextCure Newsroom

Piper Sandler Maintains NextCure(NXTC.US) With Buy Rating, Maintains Target Price $3

Futu NewsDec 6, 2024 20:31

NextCure Is Maintained at Buy by HC Wainwright & Co.

Dow JonesNov 12, 2024 02:35

H.C. Wainwright Maintains NextCure(NXTC.US) With Buy Rating, Cuts Target Price to $4

Futu NewsNov 8, 2024 20:35

Needham Maintains NextCure(NXTC.US) With Buy Rating, Cuts Target Price to $3

Futu NewsNov 8, 2024 18:33

NextCure's Strategic Shift and Financial Stability Drive Buy Rating

TipRanksNov 8, 2024 18:22

NextCure Price Target Maintained With a $4.00/Share by Needham

Dow JonesAug 2, 2024 20:21

NextCure Analyst Ratings

BenzingaAug 2, 2024 20:10

Piper Sandler Maintains NextCure(NXTC.US) With Buy Rating, Maintains Target Price $3

Futu NewsAug 2, 2024 19:31

Piper Sandler Keeps Their Buy Rating on NextCure (NXTC)

TipRanksAug 2, 2024 19:08

Buy Rating for NextCure Supported by Promising Clinical Results and Strong Financial Position

TipRanksAug 2, 2024 18:36

Needham Maintains NextCure(NXTC.US) With Buy Rating, Maintains Target Price $4

Futu NewsAug 2, 2024 18:31

NextCure Analyst Ratings

BenzingaJun 3, 2024 18:50

HC Wainwright & Co. Reiterates Buy on NextCure, Maintains $8 Price Target

BenzingaJun 3, 2024 18:50

NextCure Analyst Ratings

BenzingaMay 31, 2024 18:30

HC Wainwright & Co. Reiterates Buy on NextCure, Maintains $8 Price Target

BenzingaMay 31, 2024 18:30

Buy Rating Affirmed on NextCure's NC410 Promising Clinical Outcomes in MSS-CRC and Ovarian Cancer

TipRanksMay 31, 2024 18:21

Needham: Reiterates the NextCure (NXTC.US) rating and adjusted from buy to buy rating, target price is $4.00.

Zhitong FinanceMay 4, 2024 04:10

NextCure Analyst Ratings

BenzingaMay 4, 2024 04:05

Buy Rating Affirmed for NextCure Amid Promising Oncology Treatment Prospects and Solid Financials

TipRanksMay 3, 2024 20:40

Promising Clinical Outlook for NextCure's Novel ADC LNCB74 Spurs Buy Rating

TipRanksApr 8, 2024 23:50